Reprint
Immunotherapy in Hepatocellular Carcinoma
Edited by
April 2023
276 pages
- ISBN978-3-0365-6691-7 (Hardback)
- ISBN978-3-0365-6690-0 (PDF)
This book is a reprint of the Special Issue Immunotherapy in Hepatocellular Carcinoma that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of the art in the immunotherapy of HCC from both the basic and clinical perspectives, and outline future perspectives for improving therapies.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
cancer immunotherapy; TCGA; mutations; copy number variations; microRNAs; PD-1; PD-L1; hepatocellular carcinoma; predictive factors; immunotherapy; immune checkpoint inhibition; check-point inhibitors; liver disease; immunotherapy; outcome; immunotherapy; biomarkers; combination immunotherapy; immune-related adverse events (irAEs); hepatocellular carcinoma (HCC); alpha fetoprotein response; immune checkpoint inhibitor; unresectable hepatocellular carcinoma; hepatocellular carcinoma; a disintegrin and metalloprotease 9; nivolumab; natural killer; immunotherapy; hepatocellular carcinoma; immunotherapy; immune checkpoint inhibitor; PD-1; CTLA-4; combination therapy; hepatocellular carcinoma; immune checkpoint inhibitor; PD-1 antibody; PD-L1 antibody; anti-VEGF inhibitor; hepatocellular carcinoma; molecular classification; immune phenotype; immune checkpoint inhibitor; stem cell marker; oncogenic signal; β-catenin; genetic alteration; liver cancer; immune checkpoint inhibitor; effectiveness; safety; HCC; liver cancer; molecular-targeted agent; TACE; tyrosine kinase inhibitor; CD14+ cells; hepatocellular carcinoma; programmed death 1 ligands; hepatocellular carcinoma; immunotherapy; translational approaches; combination therapies; therapy resistance; hepatocellular carcinoma; immunotherapy; combination therapy; predictive markers; tissue-resident memory CD8 T cells; hepatocellular carcinoma; immune checkpoint blockade; immunotherapy